Niacinamide—also called nicotinamide—is an amide form of vitamin B3 used in leave-on skincare. It is one of beauty’s most versatile ingredients, but versatility creates a communication problem: mechanistic cell work, cosmetic appearance trials and medical studies are often flattened into one oversized claim. This research library keeps those evidence layers separate.
This page is designed for consumers, formulators, beauty writers and editors who need a citable map rather than another list of benefits. It complements GlowBareSkin’s guides to niacinamide concentration, ingredient percentages and the DERMIS evidence-grading framework.
Niacinamide evidence at a glance
| Question | Best-supported answer | Important boundary |
|---|---|---|
| Does it support the barrier? | Mechanistic and human data report increased stratum-corneum lipids and reduced transepidermal water loss in dry skin. | Results depend on concentration, vehicle, population and comparator. |
| Can it improve uneven-looking tone? | Vehicle-controlled studies report reduced visible hyperpigmentation; melanosome-transfer inhibition is a proposed mechanism. | This is not proof that cosmetics treat melasma or other pigment disorders. |
| Can it improve signs of photoageing? | A 5% split-face study reported changes in fine lines, spots, blotchiness and sallowness over 12 weeks. | One studied formulation cannot validate every 5% serum. |
| Does it reduce oil? | Two studies of a 2% moisturizer found changes in sebum measures, with results differing between populations. | Lower shine is not equivalent to acne prevention. |
| Is more better? | No comparative evidence establishes a universal dose-response advantage for high-percentage retail serums. | Total formula, repeated exposure and tolerance matter. |
The GlowBareSkin NIA-5 transfer check
Before transferring a niacinamide claim from a paper to a product, check five variables: Name, Inclusion level, Architecture, Audience and Assessment.
- Name: Was the study about niacinamide/nicotinamide, nicotinic acid, an oral supplement or a combination formula?
- Inclusion level: Was the tested percentage disclosed and does it match the product being discussed?
- Architecture: What was the vehicle—gel, cream, emulsion or multi-active formula—and what was the comparator?
- Audience: Were participants selected for dry skin, photoageing, pigmentation, oiliness or a diagnosed condition?
- Assessment: Was the endpoint instrumental, investigator-rated, participant-reported, microscopic or biochemical?
A match on only “niacinamide” is weak transfer. A study of 5% niacinamide in a controlled split-face emulsion cannot automatically prove that a different 10% water serum is more effective.
Evidence library
1. Skin-barrier lipids and water loss
Tanno and colleagues studied cultured keratinocytes and topical nicotinamide in dry skin. They reported increased synthesis of ceramides, free fatty acids and cholesterol, together with lower transepidermal water loss after topical application. This is useful because the outer barrier relies on an organised lipid matrix—not because “more ceramides” is automatically visible as a consumer result. Read the primary PubMed record.
The study supports a plausible barrier pathway and a human water-loss endpoint. It does not show that niacinamide alone repairs every impaired barrier, nor does it compare contemporary retail formulas head-to-head.
2. Visible pigmentation and melanosome transfer
Hakozaki and colleagues combined laboratory models with vehicle-controlled clinical work. Niacinamide did not work as a direct tyrosinase inhibitor in their system; instead, the authors reported inhibition of melanosome transfer from melanocytes to keratinocytes and a reduction in visible hyperpigmentation after four weeks. See the 2002 clinical and mechanistic study.
A later study reported dose-dependent, reversible changes in hyperpigmented lesions in a split-face design, reinforcing that the mechanism and visible endpoint deserve separate descriptions. See Greatens et al. The careful editorial phrasing is “may improve the appearance of uneven pigmentation,” not “stops melanin” or “treats pigmentation.”
3. Fine lines, blotchiness and sallowness
In a randomized split-face study, Bissett and colleagues evaluated a 5% niacinamide moisturizer over 12 weeks and reported improvements in fine lines and wrinkles, hyperpigmented spots, red blotchiness and sallowness, among other measured properties. The study record supports several cosmetic appearance claims.
However, this remains product-and-protocol evidence. It does not prove that 5% is universally optimal, that effects continue indefinitely, or that a product with the same headline percentage reproduces the same vehicle, stability, exposure and compliance.
4. Facial sebum
Draelos and colleagues studied a 2% niacinamide moisturizer in separate Japanese and US trials. The Japanese group showed reduced sebum excretion rate after two and four weeks. In the US split-face study, casual sebum levels fell after six weeks while sebum excretion rate did not fall significantly. That divergence is exactly why single-sentence benefit lists are inadequate. Read the full abstract and design details.
The defensible synthesis is that 2% niacinamide showed a sebum-related signal in these protocols, not that niacinamide is a universal oil-control treatment or that it prevents comedones.
5. Acne and medical-context studies
A double-blind trial compared 4% nicotinamide gel with 1% clindamycin gel in moderate inflammatory acne. Both groups improved, with no statistically significant difference in the reported physician global evaluation. This is a medical-context study with a particular gel, population and comparator; it should not be used to market an ordinary cosmetic moisturizer as an acne treatment. See Shalita et al.
Likewise, a niacinamide-versus-hydroquinone split-face trial in melasma belongs in a clinician-guided disease context. It contributes evidence but does not convert cosmetic niacinamide into a substitute for diagnosis or prescribed care. See Navarrete-Solís et al.
What concentration can the evidence establish?
Published topical studies include 2%, 4% and 5% contexts, but they answer different questions. Comparing percentages across unrelated vehicles and endpoints is not a dose-response trial. A strong product decision therefore considers the entire formula and cumulative routine—not only the largest number on the front label. If niacinamide appears in several products, count repeated exposure and monitor comfort.
Citation desk
| Source | Design | Scoped fact suitable for citation | Limitation |
|---|---|---|---|
| Tanno 2000 | Cell work plus topical human assessment | Nicotinamide increased several barrier lipids and reduced water loss in dry skin. | Limited transfer to dissimilar finished products. |
| Hakozaki 2002 | Models plus vehicle-controlled trials | Niacinamide inhibited melanosome transfer in the model and reduced visible pigmentation clinically. | Not evidence of disease treatment. |
| Bissett 2005 | Randomized split-face, 5%, 12 weeks | Multiple ageing-appearance endpoints improved versus control. | One formulation and protocol. |
| Draelos 2006 | Two trials, 2% moisturizer | Sebum measures changed, with population-specific differences. | Not acne-prevention evidence. |
Methodology and limitations
GlowBareSkin reviewed accessible primary records for topical niacinamide studies relevant to barrier function, visible pigmentation, ageing appearance, sebum and selected medical contexts. Priority was given to human controlled studies, supported by mechanistic work where it explained rather than replaced clinical evidence. This is a structured narrative evidence map, not a systematic review or meta-analysis.
Limitations include small or narrowly selected samples, short study durations, inconsistent endpoint definitions, incomplete reporting of vehicle details in abstracts, industry involvement in parts of the literature and difficulty separating an ingredient from its finished formula. Absence from this library does not prove absence of evidence. Review date: 13 August 2026.
FAQs
Is niacinamide the same as niacin?
No. Niacinamide/nicotinamide is the amide form of vitamin B3. Nicotinic acid is a different form and can behave differently, including a flushing response in some contexts.
Is 10% niacinamide more effective than 5%?
Current cited evidence does not establish a universal superiority of 10%. Stronger concentration does not compensate for a poor vehicle, instability or irritation.
Can niacinamide replace sunscreen?
No. Appearance or pigmentation findings do not replace tested sun protection. Sunscreen remains a separate protective step.
Can sensitive skin use niacinamide?
Many people tolerate it, but any ingredient or formula can irritate. Start with one niacinamide product, patch test when appropriate and reduce frequency if discomfort develops.
How to cite this resource
Key takeaways
- Human evidence supports several topical niacinamide endpoints, but those endpoints come from different formulas and populations.
- Barrier, pigmentation, ageing-appearance and sebum findings should be cited separately.
- Published 2%, 4% and 5% studies do not establish that a 10% retail serum is universally superior.
- Medical-context trials cannot be transferred into disease-treatment claims for ordinary cosmetics.
- The NIA-5 check helps writers match a claim to the studied name, inclusion level, formula architecture, audience and assessment.
Suggested citation: Bathula Meghana. “Niacinamide for Skin: Research Library & Evidence Map.” GlowBareSkin, reviewed 13 August 2026.
Original GlowBareSkin charts on this page may be reused unaltered for editorial or educational purposes with visible attribution to Bathula Meghana and GlowBareSkin and a link to this article.
Educational disclaimer: This article is for general education and does not diagnose or treat a medical condition. Seek qualified medical advice for persistent irritation, acne, melasma or other skin concerns.
